Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010629 · ClinicalTrials.gov registry record · Phase 2
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
A Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma, sponsored by Glenn J. Hanna.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05010629 is a Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma that is active but no longer recruiting, run by Glenn J. Hanna. The registered enrollment target is 35 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05010629, a Phase 2 study of Metastatic Cancer and Adenoid Cystic Carcinoma, is active but no longer recruiting, sponsored by Glenn J. Hanna.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG 9-ING-41
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2027-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010629
The ClinicalTrials.gov registry entry for NCT05010629 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT05010629 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05010629 about?
NCT05010629 is a clinical study titled "9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma". This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
What is the current status of trial NCT05010629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2021-09-14. Estimated completion is 2027-04-12.
What conditions does trial NCT05010629 study?
This clinical trial studies the following conditions: Metastatic Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Recurrent Salivary Gland Cancer.
What interventions are being tested in trial NCT05010629?
The interventions under investigation include: Carboplatin (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT05010629?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010629 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.